Cello Group (LON:CLL)‘s stock had its “buy” rating reiterated by equities researchers at FinnCap in a research report issued to clients and investors on Monday. They presently have a GBX 135 ($1.81) price target on the stock. FinnCap’s target price suggests a potential upside of 7.14% from the stock’s previous close.
Separately, N+1 Singer restated a “buy” rating and issued a GBX 131 ($1.75) target price on shares of Cello Group in a report on Wednesday, September 20th.
Cello Group (CLL) opened at GBX 126 ($1.69) on Monday. Cello Group has a 1-year low of GBX 95.20 ($1.27) and a 1-year high of GBX 140 ($1.87).
Cello Group Company Profile
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
What are top analysts saying about Cello Group plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cello Group plc and related companies.